Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Traws Pharma, Inc. Director's Dealing 2013

Jul 25, 2013

35199_dirs_2013-07-24_ea8b3a67-a5d6-43dc-9b1d-cf04c2753408.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2013-07-24

Reporting Person: Altland James (SVP, Finance & Corp. Develop.)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to purchase) $6.00 2017-08-01 Common Stock (60015) Direct
Stock Option (right to purchase) $5.76 2020-03-17 Common Stock (3750) Direct
Stock Option (right to purchase) $5.76 2020-03-17 Common Stock (15003) Direct
Stock Option (right to purchase) $6.13 2020-12-10 Common Stock (11252) Direct
Stock Option (right to purchase) $6.13 2021-12-05 Common Stock (2960) Direct
Stock Option (right to purchase) $13.28 2022-12-19 Common Stock (3750) Direct
Stock Option (right to purchase) $13.28 2022-12-19 Common Stock (18754) Direct

Footnotes

F1: This option, representing a right to purchase a total of 15,003 shares of Common Stock, is immediately exercisable and vests over 4 years from March 17, 2010, with 25% vesting on March 17, 2011 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.

F2: This option, representing a right to purchase a total of 18,754 shares of Common Stock, is immediately exercisable and vests over 4 years from December 18, 2012, 25% vesting on December 18, 2013 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.